Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: A clinicopathologic and immunohistochemical study

Bornstein, 1987, A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, N Engl J Med, 317, 408, 10.1056/NEJM198708133170703

Johnson, 1995, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis, Neurology, 45, 1268, 10.1212/WNL.45.7.1268

Drago, 1999, Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis, Arch Dermatol, 135, 1277, 10.1001/archderm.135.10.1277

Mancardi, 2000, Localized lipoatrophy after prolonged treatment with copolymer 1, J Neurol, 247, 220, 10.1007/s004150050568

Hwang, 2001, Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis, Cutis, 68, 287

Soós, 2004, Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis, Am J Clin Dermatol, 5, 357, 10.2165/00128071-200405050-00009

Edgar, 2004, Lipoatrophy in patients with multiple sclerosis on glatiramer acetate, Can J Neurol Sci, 31, 58, 10.1017/S0317167100002845

2000

Fridkis-Hareli, 1994, Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells–specificity and promiscuity, Proc Natl Acad Sci U S A, 91, 4872, 10.1073/pnas.91.11.4872

Miller, 1998, Treatment of multiple sclerosis with copolymer-1 (Copaxone). Implicating mechanisms of Th1 to Th2/Th3 immune-deviation, J Neuroimmunol, 92, 113, 10.1016/S0165-5728(98)00191-X

Ziemssen, 2002, Behandlung der Multiplen Sklerosen mit Glatiramer-Azetat, Nervenarzt, 73, 321, 10.1007/s00115-001-1257-0

Hohlfeld, 2000, The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis, J Neuroimmunol, 107, 161, 10.1016/S0165-5728(00)00233-2

Johnson, 1996, A review of the clinical efficacy profile of copolymer 1: new US phase III trial data, J Neurol, 243, S3, 10.1007/BF00873695

Requena, 2001, Panniculitis, part II: mostly lobular panniculitis, J Am Acad Dermatol, 45, 325, 10.1067/mjd.2001.114735